Spruce Biosciences SPRB Stock
Spruce Biosciences Price Chart
Spruce Biosciences SPRB Financial and Trading Overview
| Spruce Biosciences stock price | 52.14 USD |
| Previous Close | 52.36 USD |
| Open | 52.05 USD |
| Bid | 53.25 USD x 100 |
| Ask | 54.58 USD x 100 |
| Day's Range | 52 - 55.95 USD |
| 52 Week Range | 7 - 838.13 USD |
| Volume | 96.35K USD |
| Avg. Volume | 68.9K USD |
| Market Cap | 150.55M USD |
| Beta (5Y Monthly) | 3.2 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -35.82 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 149.71 USD |
SPRB Valuation Measures
| Enterprise Value | 103.59M USD |
| Trailing P/E | N/A |
| Forward P/E | 11.050506 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.1664224 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -4.009 |
Trading Information
Spruce Biosciences Stock Price History
| Beta (5Y Monthly) | 3.2 |
| 52-Week Change | -86.10% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 838.13 USD |
| 52 Week Low | 7 USD |
| 50-Day Moving Average | 54.99 USD |
| 200-Day Moving Average | 71.91 USD |
SPRB Share Statistics
| Avg. Volume (3 month) | 68.9K USD |
| Avg. Daily Volume (10-Days) | 72.94K USD |
| Shares Outstanding | 2.75M |
| Float | 2.65M |
| Short Ratio | 5.22 |
| % Held by Insiders | 3.51% |
| % Held by Institutions | 31.24% |
| Shares Short | 241.93K |
| Short % of Float | 8.88% |
| Short % of Shares Outstanding | 8.79% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:75 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -37.16% |
| Return on Equity (ttm) | -148.84% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -10360000 USD |
| EBITDA | -25841000 USD |
| Net Income Avi to Common (ttm) | -37191000 USD |
| Diluted EPS (ttm) | -35.82 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 54.08M USD |
| Total Cash Per Share (mrq) | 19.65 USD |
| Total Debt (mrq) | 7.12M USD |
| Total Debt/Equity (mrq) | 20.56 USD |
| Current Ratio (mrq) | 4.67 |
| Book Value Per Share (mrq) | 25.249 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -29332000 USD |
| Levered Free Cash Flow (ttm) | -13359500 USD |
Profile of Spruce Biosciences
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 611 Gateway Boulevard |
| ZIP | 94080 |
| Phone | 415 343 5986 |
| Website | https://sprucebio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 14 |
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Q&A For Spruce Biosciences Stock
What is a current SPRB stock price?
Spruce Biosciences SPRB stock price today per share is 52.14 USD.
How to purchase Spruce Biosciences stock?
You can buy SPRB shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Spruce Biosciences?
The stock symbol or ticker of Spruce Biosciences is SPRB.
Which industry does the Spruce Biosciences company belong to?
The Spruce Biosciences industry is Biotechnology.
How many shares does Spruce Biosciences have in circulation?
The max supply of Spruce Biosciences shares is 2.75M.
What is Spruce Biosciences Price to Earnings Ratio (PE Ratio)?
Spruce Biosciences PE Ratio is now.
What was Spruce Biosciences earnings per share over the trailing 12 months (TTM)?
Spruce Biosciences EPS is -35.82 USD over the trailing 12 months.
Which sector does the Spruce Biosciences company belong to?
The Spruce Biosciences sector is Healthcare.
Spruce Biosciences SPRB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12546.99 USD — |
-2.24
|
— — | 12513.27 USD — | 12692.24 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}